Nanjing Vazyme Biotech (688105.SH) announced a pre-loss, with an estimated net loss of 20 to 12 million yuan in 2024, narrowing the loss.

Nanjing Vazyme Biotech (688105.SH) released its 2024 annual performance forecast, with the company expecting a net loss attributable to owners of the parent company of 12 to 20 million yuan, a narrowing of losses; and a net loss attributable to owners of the parent company excluding non-recurring gains and losses of 77 to 85 million yuan, also a narrowing of losses.